Home screening options for cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Unidos Contra el VPH initiative aims to explore alternative methods for cervical cancer screening that individuals can perform at home. The study compares the effectiveness of in-home HPV self-sampling using vaginal swabs and urine tests against traditional in-clinic Pap smears with HPV testing. By assessing these methods, the study seeks to improve screening completion rates and understand participant beliefs and preferences regarding these options. This approach addresses barriers faced by individuals who may find it difficult or uncomfortable to visit a clinic for screening.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals with a cervix who are 30-65 years and have not undergone a Pap test in at least three years.

Exclusion Criteria:

* Having had a hysterectomy or a personal history of cervical cancer.

Where it's running

• Project Vida Health Center
  El Paso, Texas, United States Recruiting

Study contacts

• Study coordinator: Jessica Calderón-Mora, DrPH
• Email: jessica.calderonmora@austin.utexas.edu
• Phone: 915-443-0272

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderately hypofractionated radiotherapy after hysterectomy for cervical cancer

  This study tests whether a shorter, moderately intensified radiotherapy course after surgery is safe and effective for patients with cervical cancer.

  Recruiting at 2 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07684508

• Cantharidin and occlusion in verruca epithelium: testing a topical treatment for common warts

  This Phase 3 study tests VP-102/TO-208 (cantharidin) vs. a vehicle to see if it clears common warts in people 2 years and older who have a normal immune system.

  Recruiting at 14 sites Phase 3 Verrica Pharmaceuticals Inc. · San Diego, California and 19 other locations · NCT07637734

• DARE-HPV: testing a two-dose, two-duration approach to clear persistent hrHPV in women

  This trial tests whether DARE-HPV can clear persistent high-risk HPV in premenopausal women aged 22–50, using two doses and two treatment lengths against a placebo.

  Recruiting at 11 sites Phase 2 Daré Bioscience, Inc. · Mobile, Alabama and 10 other locations · NCT07601074

• Omitting postoperative radiation after HPV-related oropharyngeal cancer guided by ctHPVDNA monitoring

  This study tests whether some patients with HPV-related OPSCC can skip postoperative radiation after surgery if their tumors are low risk and ctHPVDNA looks negative.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT07513389

• Long-term follow-up of cantharidin (YCANTH/VP-102/TO-208) treatment for common warts

  This follow-up will try applying cantharidin (YCANTH/VP-102/TO-208) every ~21 days for up to four applications to see if it safely clears remaining common warts in people who completed earlier COVE studies.

  Recruiting at 12 sites Phase 3 Verrica Pharmaceuticals Inc. · Saint Augustine, Florida and 11 other locations · NCT07457918

• Vaginal Gel to Help HPV Clear and CIN Regress in Women with CIN1/2

  This trial tests whether a Coriolus versicolor-based vaginal gel can help HPV go away and CIN1/2 lesions improve in women aged 30–50.

  Recruiting at 2 sites University of Aarhus · Horsens and 1 other locations · NCT07429071

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.